Credit: Shutterstock photoSurface Oncology, a clinical-stage biotech developing next generation antibody cancer therapies, filed on Friday with the SEC to raise up to $75 million in an initial public offering.
The Cambridge, MA-based company was founded in 2014 and booked $13 million in sales for the 12 months ended December 31, 2017. It plans to list on the Nasdaq under the symbol SURF. Surface Oncology filed confidentially on November 17, 2017. Goldman Sachs, Cowen & Company and Evercore ISI are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Cancer biotech Surface Oncology files for a $75 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
